Produkty 61585-29-3

CAS 61585-29-3 występuje w naszej ofercie pod nazwami: Calcifediol EP Impurity A, Calcifediol Impurity 1（Calcifediol EP Impurity A）, 25-Hydroxylumisterol. Oferty producentów: Chemat Brand, Hubei YoungXin, TRC. Dostępne opakowania: on request, 10mg, 25mg, 50mg, 100mg, 200mg.

Calcifediol EP Impurity A
Chemat Brand
  • opakowanie: on request
  • Warianty: 1
Zobacz produkt
Calcifediol Impurity 1（Calcifediol EP Impurity A）
Hubei YoungXin
  • opakowanie: 10mg, 25mg, 50mg, 100mg
  • Warianty: 5
Zobacz produkt
25-Hydroxylumisterol
TRC
  • opakowanie: 25mg
  • Warianty: 1
Zobacz produkt
Wzór strukturalny: {0} (CAS {1})

(3S,9R,10S,13R,14R,17R)-17-[(2R)-6-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol (CAS 61585-29-3) to związek chemiczny o wzorze sumarycznym C27H44O2 i masie molowej 400.6 g/mol. Nazwa systematyczna IUPAC: (3S,9R,10S,13R,14R,17R)-17-[(2R)-6-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol. InChIKey: JJFYNCJHSCTBPW-MKBCXXKJSA-N.

Dane identyfikacyjne
Wzór sumarycznyC27H44O2
Masa molowa400.6 g/mol
Nazwa IUPAC(3S,9R,10S,13R,14R,17R)-17-[(2R)-6-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol
InChIKeyJJFYNCJHSCTBPW-MKBCXXKJSA-N
SMILESC[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@@H]3C2=CC=C4[C@]3(CC[C@@H](C4)O)C)C

Dane obliczone przez PubChem (NCBI)

Synonimy: 25-Hydroxylumisterol, Calcifediol EP Impurity A, 9beta,10alpha-cholesta-5,7-diene-3beta,25-diol, Calcifediol Monohydrate EP Impurity A, JJFYNCJHSCTBPW-MKBCXXKJSA-N, (3beta,9beta,10alpha)-Cholesta-5,7-diene-3,25-diol, CALCIFEDIOL MONOHYDRATE IMPURITY A [EP IMPURITY], Cholesta-5,7-diene-3,25-diol, (3beta,9beta,10alpha)-
Powiązane formy tego związku
(3S,9S,10R,13R,14R,17R)-17-[(2R)-6-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol C27H44O2
Izomery (ten sam wzór sumaryczny)
(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol C27H44O2
[(2E)-3,7-dimethylocta-2,6-dienyl] (4E,8E)-5,9,13-trimethyltetradeca-4,8,12-trienoate C27H44O2
trans-(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol C27H44O2
(1S)-3-[(Z)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-1,2,3,3a,6,7-hexahydroinden-4-yl]ethenyl]-4-methylcyclohex-3-en-1-ol C27H44O2
(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-7,7,7-trideuterio-6-hydroxy-6-(trideuteriomethyl)heptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol C27H44O2
(3S,8S,9S,10R,13R,14S,17R)-17-[(2R)-4-[(2S)-3,3-dimethyloxiran-2-yl]butan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol C27H44O2
(1R,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol C27H44O2
(8S,9S,10R,13R,14S,17R)-17-[(2R,6R)-7-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one C27H44O2
(3S,8S,9S,10R,13R,14S,17R)-3-hydroxy-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,3,4,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-7-one C27H44O2
trans-(1R,3S,5E)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol C27H44O2
(6R)-6-[(3S,10R,13R,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylheptan-3-one C27H44O2